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The role of HbA1c as a screening and diagnostic test for
diabetes mellitus in Ankara
Zeynep GİNİŞ1, Gülfer ÖZTÜRK1, Rana SIRMALI1, Ali YALÇINDAĞ1, Yakup DÜLGEROĞLU1,
Tuncay DELİBAŞI2, Namık DELİBAŞ1

Aim: This study investigated the value of HbA1c as a screening and diagnostic test for diabetes mellitus (DM) in highrisk Turkish individuals.
Materials and methods: A total of 295 participants were successfully screened. Patients were divided into 4 groups
based on their oral glucose tolerance test results, according to criteria put forth by the American Diabetes Association;
120 (40.7%) had normoglycemia, 44 (14.9%) had DM, 62 (21%) had impaired fasting glucose, and 69 (23.4%) had
impaired glucose tolerance.
Results: With a cut-off value for the diagnosis of DM of 6.1%, HbA1c had a sensitivity of 81.8% and a specificity of 80%,
with positive and negative predictive values of 80.2% and 81.05%, respectively. A sensitivity of 56.8% and a specificity of
89.2% were calculated for a cut-off value of 6.5%. Both fasting plasma glucose and 2-h plasma glucose levels were found
to correlate moderately with HbA1c levels (r = 0.47, P = 0.001 and r = 0.52, P = 0.000, respectively).
Conclusion: The results of our observations suggest that HbA1c could be used to make a diagnosis of DM in the
Turkish population. However, further studies are needed to determine the most accurate cut-off value. Standardization
of HbA1c assays used worldwide is also of great importance.
Key words: HbA1c, diabetes mellitus, diagnosis, oral glucose tolerance test

Introduction
Diabetes mellitus (DM) is one of the most commonly
encountered chronic disorders. By 2030, the
worldwide prevalence of adult DM is expected to
rise to 7.7%, which roughly translates to 439,000,000
affected individuals (1). Based on current
recommendations, a diagnosis of DM requires the
presence of a fasting plasma glucose concentration of
≥126 mg/dL, or a 2-h plasma glucose level of ≥200
mg/dL on an oral glucose tolerance test (OGTT). On
the other hand, international committee members
selected by the American Diabetes Association (ADA)
and the Alliance for European Diabetes Research
(EURADIA) recently suggested that glycosylated

hemoglobin (HbA1c) could be used as an alternative
for making a diagnosis. (2). The committee concluded
that an HbA1c level of ≥6.5% was diagnostic for DM,
without requiring a determination of blood/plasma
glucose levels. However, the use of standard glucose
measurements is still recommended for individuals
when HbA1c assays are deemed unreliable (3)
HbA1c is formed as a result of the addition of a
stable glucose molecule to the N-terminal group
of an HbA0 molecule via a nonenzymatic glycation
process (4), and is considered a reliable indicator of
the glycemic status of the previous 3 months (5).
Despite the cloud of controversy regarding the
limitations of HbA1c for making a diagnosis of DM,
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many experts believe that HbA1c may be superior
to the OGTT in daily clinical practice. The Turkish
Endocrine Society does not consider HbA1c a
reliable diagnostic test for DM, citing insufficient
standardization of available HbA1c assays as well as
the inconclusive results concerning the optimal cutoff value(6).
The aim of this study was to investigate the value
of HbA1c as a screening and diagnostic test for DM
in high-risk Turkish individuals.
Materials and methods
Patient selection and initial evaluation
This study was undertaken in the Department of
Endocrinology at Dışkapı Yıldırım Beyazıt Training
and Research Hospital with the approval of the local
ethics committee. Patients with known risk factors
for developing type 2 diabetes mellitus (T2DM), such
as a family history of DM or impaired fasting glucose,
who presented to the outpatient clinic between
September 2010 and April 2011 were approached for
inclusion in this study, and consenting patients were
enrolled. A detailed history was obtained for each
patient, followed by a thorough physical examination
including anthropometric measurements and
determination of arterial blood pressure. Height,
weight, waist circumference, and systolic and diastolic
blood pressure measurements were recorded for each
patient, and body mass indices were calculated using
the formula BMI = (weight in kg / height in m2).
Blood sampling and laboratory assays
For each patient, blood samples were obtained at 0800
hours following a 12-h fast, from the antecubital vein
in a sitting position, for the determination of HbA1c
as well as baseline/fasting blood glucose level. All
patients were then subjected to a 75-g OGTT (on the
same day), and second blood samples were obtained
2 h after glucose loading.
HbA1c measurements were made using an
NGSP-approved latex agglutination inhibition
method on an Advia 2400 (Siemens Healthcare
Diagnostics, Germany) analyzer. Blood samples were
first incubated for at least 5 min with a hemoglobindenaturing reagent to allow for lyses of erythrocytes.
Proteases and hemoglobin chains within the
resultant mixture were then hydrolyzed followed by

determination of total hemoglobin levels. HbA1c
levels were determined by agglutination with antiHbA1c antibodies. The intraassay coefficients of
variation for normal and abnormal patients were
1.2% and 0.8%, respectively, with respective total
coefficients of variation of 2.0% and 1.8%. Glucose
measurements were made on the same day as HbA1c
measurements, using the glucose oxidation method
on an Advia 2400 analyzer. Subjects were categorized
into 4 groups based on their OGTT results, according
to criteria put forth by the ADA: normoglycemic,
impaired fasting glucose (IFG), impaired glucose
tolerance (IGT), and DM.
Statistical analyses were performed using SPSS
17. Values for HbA1c and blood glucose levels
are provided as mean ± standard deviation. The
sensitivity, specificity, negative predictive, and positive
predictive values for both tests were calculated by
plotting a receiver operating characteristic (ROC)
curve. Correlation analyses between fasting plasma
glucose, 2-h plasma glucose, and HbA1c levels were
performed using Spearman’s correlation test. A
P-value of less than 0.05 was considered indicative of
statistical significance.
Results
A total of 295 consenting participants (79 male
and 216 female) were included in the final analysis.
Based on OGTT results and according to criteria put
forth by the ADA, 120 individuals were categorized
as normoglycemic, 44 had DM, 63 had IFG, and
69 had IGT. The demographic characteristics and
laboratory findings of the study population have
been summarized in the Table.
The OGTT was considered the gold-standard test
for the diagnosis of DM. The area under the ROC
curve for the diagnosis of DM was 0.85 (P < 0.001)
(Figure 1). With a cut-off value of 6.1%, HbA1c had a
maximal sensitivity and specificity of 81.8% and 80%,
respectively, with a positive predictive value (PPV)
of 80.2% and a negative predictive value (NPV) of
81.05%. With a cut-off value of 6.5%, the sensitivity
of HbA1c was 56.8% with a specificity of 89.2%.
The area under the curve (AUC) for impaired
glucose tolerance was 0.67 (P < 0.001). HbA1c had a
sensitivity of 63.8%, specificity of 60%, PPV of 61.4%
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Table. Demographic characteristics and laboratory findings of study population.
Total
N = 295

NG
N = 120

DM
N = 44

IFG
N = 62

Age, years

48.98 ± 12.22

Fasting plasma glucose

101.4 ± 19.60

45.97 ± 12.22

52 ± 12.39

50.32 ± 10.70

51.11 ± 12.50

89.16 ± 11.56

139.88 ± 18.71

108.09 ± 6.89

102.31 ± 14.68

2-h plasma glucose

140.81 ± 61.33

100 ± 19.73

255.5 ± 56.32

110.53 ± 20.99

165.60 ± 17.18

6.0 ± 0.80

5.75 ± 0.73

6.80 ± 0.93

5.83 ± 0.57

6.08 ± 0.68

30.47 ± 5.55

28.93 ± 6.00

32.39 ± 4.67

31.38 ± 4.96

30.93 ± 4.90

SBP, mm/Hg

124.24 ± 16.42

121.58 ± 14.68

128.81 ± 19.65

125.32 ± 16.61

125.94 ± 14.21

DBP mm/Hg

77.39 ± 11.13

76.25 ± 10.94

77.88 ± 13.47

78.46 ± 10.02

79.24 ±10.48

WC, cm

96.48 ± 15.66

91.67 ± 13.87

102.20 ± 15.08

97.19 ± 15.14

102.75 ± 16.23

Parameter

HbA1c, %
BMI, kg/m

2

IGT
N = 69

Values provided as mean ± standard deviation; BMI, body mass index; HbA1c, glycosylated hemoglobin; NG, normoglycemic group;
DM, overt diabetes mellitus group; IFG, impaired fasting glucose group; IGT, impaired glucose tolerance group; SBP, systolic blood
pressure; DBP, diastolic blood pressure; WC, waist circumference.

and NPV of 62.37% with a cut-off value of 5.7%. A
positive correlation was observed between HbA1c,
fasting plasma glucose (r = 0.47, P = 0.001), and 2-h
plasma glucose (r = 0.52, P = 0.000) glucose levels in
patients with DM (Figures 2 and 3).
Discussion
Recently, the ADA has recommended that HbA1c
be used for the diagnosis of DM with a cut-off
value of ≥6.5%, taking into consideration the strong
association between this cut-off value and the
prevalence of retinopathy (2). A similar association
between HbA1c and risk of developing both diabetes
and cardiovascular disease has also been reported in
adults (7).

status prior to blood sampling. Pretest exercise and
calorie restriction are other factors that may affect
interpretation of results (10). HbA1c does not
require fasting and has an analytical variation of less
than 2%, which overcomes most of the difficulties
mentioned above. The main disadvantages of this
test are the high cost and the need for determination
by a method certified by the NGSP, such as highperformance liquid chromatography (HPLC).
HbA1c shows very little daily variation and is widely
believed to be a more suitable reflection of chronic
glycemic status (11).

The accuracy and precision of HbA1c assays has
improved greatly in recent years with the advent
of technological advancements and widespread
availability of international standardization (8).
Determination of HbA1c has now become more
advantageous than plasma glucose measurements,
since HbA1c is biologically more stable and remains
largely unaffected in the short term by nutritional
status, stress, or other disorders (9)

Kumar et al. (11) reported on a sensitivity of 65%
and a specificity of 88%, with positive and negative
predictive values of 75.2% and 96.5%, respectively,
with a cut-off value of 6.5%. Peter et al. (12) reported
that an HbA1c value of 6.5% could distinguish
diabetic patients from nondiabetic patients with a
specificity of 98.7%. However, in the same study,
the investigators observed a very low sensitivity of
46.8%, which translates into a missed diagnosis in
more than half of the patients who actually have DM.
In our study population, an HbA1c value of 6.5% had
a sensitivity of 56.8% for making a diagnosis of DM,
a finding consistent with results of previous reports.

Several problems are associated with blood
glucose measurements, such as interindividual
biological variations and preanalytic variables like
sampling method (e.g., at room temperature, glucose
levels decrease by 3–8 mg/dL per hour) and fasting

The low sensitivity of HbA1c as a diagnostic test
for DM could be attributed to several factors, such
as the presence of iron deficiency anemia or another
disorder affecting hemoglobin turnover, as well as
several hereditary and environmental factors (13).
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Figure 1. Receiver operating characteristic curve for HbA1c in
patients with diabetes mellitus.

Nearly 50% of variations in HbA1c levels may be
explained by changes in blood sugar profile (14).
While HbA1c is a measure of chronic glycemic control,
determination of blood glucose levels only represents
glucose concentration at the time of sampling and
may not correctly reflect a patient’s glycemic status
over the previous months. Furthermore, results of
the OGTT may be influenced by the presence of an
active infection, physical activity, and diet (12). All
patients were informed regarding the possible effects
of such confounding factors, and blood sampling was
scheduled taking these factors into consideration.
Several studies have investigated the value of
HbA1c for the diagnosis of DM with a cut-off level
of 6.1%. In such a study by Tavintharan et al. (15), a
sensitivity of 81% was reported with a specificity of
84%. Similarly, Ko et al. (16) reported on a sensitivity
and specificity of 77.5% and 78.8%, respectively.
Comparable results were observed in our study with
a cut-off value of 6.1% (sensitivity, 81.8%; specificity,
80%; PPV, 80.2%; NPV, 81.05%).
Numerous studies have attempted to investigate
the role of HbA1c as a diagnostic test for DM, by
comparing it with the OGTT as the gold-standard
(17–19). Colagiuri et al. (17) evaluated the screening
strategies that included measurement of HbA1c

100.00

150.00
200.00
Fasting plasma glucose

250.00

Figure 2. Correlation curve for fasting plasma glucose and
HbA1c (r = 0.47, P = 0.001).

in a population (N = 10,447) without previously
diagnosed diabetes. In their study, a cut-off value
of 5.3% for HbA1c had a sensitivity of 78.7% with
a specificity of 82.8% (17). Van’t Riet et al. (20) also
reported on a sensitivity of 72% with a specificity of
91% in a study of 2708 patients where a cut-off value
of 5.8% was used. The significantly lower number of
participants in our study compared to the Colagiuri
and van’t Riet studies may explain the discrepancies
in our findings, although our results are comparable
to those reported in a study by Kumar et al. (11) on
individuals whose DM status was unknown, where a
cut-off value of 6.1% was used.
Santos-Rey et al. (21) investigated the role of
HbA1c with a cut-off value of 5.4% for the diagnosis
of IGT. They reported a sensitivity of 85%, a specificity
of 73%, and a NPV of 97%. A similar analysis in
our study with a cut-off value of 5.7% produced a
sensitivity of 60% with a specificity of 63.8%, a PPV
of 61.4%, and a NPV of 62.37%. Results of studies on
the potential role of HbA1c for detecting individuals
at risk of developing IGT remain inconclusive, and
further studies are needed to fully elucidate its value
as a diagnostic test.
Van’t Riet et al. (20) reported on a significant,
albeit moderate, correlation between HbA1c and
fasting plasma glucose (r = 0.57) and 2-h plasma
glucose (r = 0.35) levels. It was suggested that
1433
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as well as the neglecting of several cofactors such as
age, sex, and ethnic characteristics (25).

10.00
9.00

In a study from Turkey, Köşüş et al. (26)
recommended the glucose challenge test (GCT) as an
international screening method and suggested that
the GCT was also suitable for Turkish women. The
place of residence as well as race needed to be taken
into consideration to establish the best cut-off level
for the GCT, since ethnic and environmental factors
might contribute to the occurrence of gestational
DM.

HbA1c

8.00
7.00
6.00
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4.00
0.00

100.00
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400.00
2-h plasma glucose
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Figure 3. Correlation curve for 2-h plasma glucose and HbA1c
(r = 0.52, P = 0.000).

HbA1c and glucose go through different processes,
particularly during the period between impaired
glucose tolerance and the development of overt
DM. The extent of glycosylation is known to show
individual variability. Potential mechanisms include
genetic characteristics (22), age (23), variations
in surrounding conditions of erythrocytes (24),
heterogeneity in the life cycle of erythrocytes, and
ethnic variations. We also managed to demonstrate
a statistically significant positive correlation between
HbA1c and fasting plasma glucose (r = 0.47) and 2-h
plasma glucose (r = 0.52) levels.
Riet et al. (20) reported that weak positive
correlations between HbA1c and fasting plasma
glucose levels (r = 0.46), as well as 2-hour plasma
glucose (r = 0.33) levels, were observed in individuals
from the general population. The correlation between
HbA1c and fasting plasma glucose and 2-h plasma
glucose levels was weaker in patients with IFG or IGT
compared to those with overt DM (r = 0.38 and r =
0.43, respectively). Although a wide range of values
have been reported for both glucose and HbA1c in
the general population, the correlation between them
is stronger in patients with DM, a finding that has
also been reiterated by van’t Riet et al. (20).
OGTT and HbA1c results may sometimes show
discordance, which is not explainable by analytical
variations alone. Such discrepancies may be attributed
to biological variations. Evaluation of HbA1c levels
still suffers from the lack of an international standard,
1434

Different ethnic groups were found to have
different sensitivity and specificity values for
HbA1c as a diagnostic test for DM, which may be
related to genetic differences in the concentration
of hemoglobin, the rates of glycation, and the
lifespan or amount of red blood cells (27). Recently,
racial and ethnic variations in HbA1c have been
reported to impact the potential utility of HbA1c as
a diagnostic test for diabetes (28). Ethnic variations
in HbA1c could not be evaluated in our study since
all participants were living in the Ankara area (29).
While HbA1c is a reliable indicator of chronic
glycemic status, 2-h glucose measurements obtained
from an OGTT are considered to reflect daily
insulin secretion. HbA1c is expected to overtake the
OGTT as the test of choice for DM, which, when it
does occur, would be considered a milestone in the
management of DM (12).
Many studies have demonstrated that HbA1c
correlates better with microvascular complications
in patients with DM (29). Zengin et al. (30)
suggested that higher HbA1c levels as a marker of
poor glycemic control were associated with thicker
corneas in T2DM. On the other hand, insulin
resistance is a better predictor for the development of
macrovascular complications (31). Insulin resistance
is even considered to be the most important risk factor
for the development of coronary artery disease (32).
In another study with conflicting results, 2-h plasma
glucose levels during an OGTT were reported to be
a better predictor than HbA1c for the development
of cardiovascular incidents (33). Similarly, Ning et
al. (34) reported a significant association between
insulin resistance and increased risk of mortality
from cardiovascular disease. However, this result was
later disputed, citing the use of different diagnostic
criteria for DM.
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Determination of HbA1c is less time-consuming
than the OGTT and is largely unaffected by fasting
status. Furthermore, HbA1c is a better predictor
of any future DM-related complications. Large
epidemiologic studies have demonstrated a
correlation between HbA1c levels and an increased
risk of developing cardiovascular disorders, not only
in patients with overt DM but also in those with IGT
(35,36).
HbA1c may be used for making a diagnosis of
T2DM in high-risk individuals. In a population
where the prevalence of DM is constantly on the
rise, there is a need for a test with high specificity to
minimize false positivity.

One of the main limitations of our study
could be the HbA1c assay used. In most of the
previous studies, the HPLC (high-performance
liquid chromatography) method was used for
the determination of HbA1c, whereas the latex
agglutination inhibition method was used in our
study, mainly because of its availability in Turkish
clinical laboratories.
Our study results suggest that HbA1c could be
used to make a diagnosis of DM in in Turkey. For
HbA1c to overtake the OGTT as a reliable test would
require the determination of an optimal cut-off value
and the use of internationally standardized assays.
Further studies on a larger scale are required in order
to validate HbA1c assays as a reliable screening and
diagnostic test for DM in Turkish individuals.
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